Severe lorlatinib-induced dyslipidaemia successfully managed with a PCSK9 inhibitor in a patient with ALK-positive non-small cell lung cancer: A case report

Journal of Clinical and Translational Endocrinology: Case Reports · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles